Abstract #0987

Prospective multi-institutional validation of IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (MULTI-IMPROD trial)

Ivan Jambor^1,2, Janne Verho¹, Otto Ettala³, Juha Knaapila³, Pekka Taimen¹, Kari Syvänen³, Aida Kiviniemi¹, Esa Kähkönen³, Ileana Montoya Perez¹, Marjo Seppänen⁴, Antti Rannikko⁵, Outi Oksanen⁵, Jarno Riikonen⁶, Sanna-Mari Vimpeli⁶, Tommi Kauko³, Harri Merisaari¹, Tarja Lamminen³, Markku Kallajoki³, Tuomas Mirtti⁷, Jani Saunavaara³, Hannu Aronen¹, and Peter J Boström³

¹University of Turku, Turku, Finland, ²Icahn School of Medicine at Mount Sinai, New York, NY, United States, ³Turku University Hospital, Turku, Finland, ⁴Satakunta Central Hospital, Pori, Finland, ⁵Helsinki University Hospital, Helsinki, Finland, ⁶Tampere University Hospital, Tampere, Finland, ⁷University of Helsinki, Helsinki, Finland

In this prospective multicenter trial, a prior developed unique MRI acquisition and reporting protocol, IMPROD bpMRI (NCT01864135), enabled the detection of 97% (143/146) of men with Gleason score ≥3+4. IMPROD bpMRI consists of T2-weighted imaging and three separate diffusion weighted imaging acquisitions with acquisition time <15 minutes. IMPROD bpMRI appears to be a powerful tool for improved prostate cancer risk stratification in men with a clinical suspicion of prostate cancer based on elevated PSA and/or digital rectal examination. Public access to all data is provided at the following addresses: http://petiv.utu.fi/improd and http://petiv.utu.fi/multiimprod

This abstract and the presentation materials are available to members only; a login is required.

Join Here